MimiVax, SurVaxM, Glioblastoma, Brain Cancer, Cancer Immunotherapy, SURVIVE Trial, Phase 2b, Oncology, Immunotherapy, Clinical Trial, Overall Survival, Progression-Free Survival, Roswell Park,

BUFFALO, N.Y., October 7, 2026 MimiVax Inc., a clinical-stage biotechnology company developing cancer immunotherapies, in collaboration with Roswell Park...